A novel gene signature based on five immune checkpoint genes predicts the survival of glioma

被引：1
作者：
Zhang W. [1 ,5 ]
Zhai Y. [2 ]
Li G. [2 ]
Jiang T. [1 ,2 ,3 ,4 ,5 ]
机构：
[1] Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing
[2] Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, No. 119 South Fourth Ring Road West, Fengtai District, Beijing
[3] Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing
[4] China National Clinical Research Center for Neurological Diseases, Beijing
[5] Chinese Glioma Genome Atlas Network (CGGA) and Asian Glioma Genome Atlas Network (AGGA), Beijing
来源：
Chinese Neurosurgical Journal | / 7卷 / 1期
基金：
中国国家自然科学基金;
关键词：
Gene signature; Glioma; Immune checkpoints; Prognosis;
D O I：
10.1186/s41016-020-00220-2
中图分类号：
学科分类号：
摘要：
Background: Glioma is the most common and fatal type of nerve neoplasm in the central nervous system. Several biomarkers have been considered for prognosis prediction, which is not accurate enough. We aimed to carry out a gene signature related to the expression of immune checkpoints which was enough for its performance in prediction. Methods: Gene expression of immune checkpoints in TGGA database was filtrated. The 5 selected genes underwent verification by COX and Lasso-COX regression. Next, the selected genes were included to build a novel signature for further analysis. Results: Patients were sub-grouped into high and low risk according to the novel signature. Immune response, clinicopathologic characters, and survival showed significant differences between those 2 groups. Terms including “naive,” “effector,” and “IL-4” were screened out by GSEA. The results showed strong relevance between the signature and immune response. Conclusions: We constructed a gene signature with 5 immune checkpoints. The signature predicted survival effectively. The novel signature performed more functional than previous biomarkers. © 2021, The Author(s).
引用
收藏
相关论文
共 18 条
  • [1] Jiang T., Mao Y., Ma W., Mao Q., You Y., Yang X., Et al., CGCG clinical practice guidelines for the management of adult diffuse gliomas, Cancer Lett., 375, 2, pp. 263-273, (2016)
  • [2] Gerber N.K., Goenka A., Turcan S., Reyngold M., Makarov V., Kannan K., Et al., Transcriptional diversity of long-term glioblastoma survivors, Neuro Oncol., 16, 9, pp. 1186-1195, (2014)
  • [3] Zhang C.B., Zhu P., Yang P., Cai J.Q., Wang Z.L., Li Q.B., Et al., Identification of high risk anaplastic gliomas by a diagnostic and prognostic signature derived from mRNA expression profiling, Oncotarget., 6, 34, pp. 36643-36651, (2015)
  • [4] Turkalp Z., Karamchandani J., Das S., IDH mutation in glioma: new insights and promises for the future, JAMA Neurol., 71, 10, pp. 1319-1325, (2014)
  • [5] Zhao Z., Meng F., Wang W., Wang Z., Zhang C., Jiang T., Comprehensive RNA-seq transcriptomic profiling in the malignant progression of gliomas, Sci Data., 4, (2017)
  • [6] Pal S., Bi Y., Macyszyn L., Showe L.C., O'Rourke D.M., Davuluri R.V., Isoform-level gene signature improves prognostic stratification and accurately classifies glioblastoma subtypes, Nucleic Acids Res., 42, 8, (2014)
  • [7] Hu X., Martinez-Ledesma E., Zheng S., Kim H., Barthel F., Jiang T., Et al., Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma, Neuro Oncol., 19, 6, pp. 786-795, (2017)
  • [8] Berghoff A.S., Kiesel B., Widhalm G., Rajky O., Ricken G., Wohrer A., Et al., Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma, Neuro Oncol., 17, 8, pp. 1064-1075, (2015)
  • [9] Calabrese C., Poppleton H., Kocak M., Hogg T.L., Fuller C., Hamner B., Et al., A perivascular niche for brain tumor stem cells, Cancer Cell., 11, 1, pp. 69-82, (2007)
  • [10] Bradshaw A., Wickremsekera A., Tan S.T., Peng L., Davis P.F., Itinteang T., Cancer stem cell hierarchy in glioblastoma multiforme, Front Surg., 3, (2016)
12